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Background
Although widely recommended, cryopreservation of sperm is sometimes not performed
for patients with Hodgkin’s lymphoma because of presumed poor sperm quality related
to the disease. We investigated sperm quality and factors determining it in untreated
patients with early stage Hodgkin’s lymphoma.
Design and Methods
Of 2362 males who participated in EORTC H6-H9 trials, 474 (20%) had data available.
Sperm quality was defined according to World Health Organization guidelines.
Determining factors were studied by logistic regression analysis.
Results
The median sperm concentration was 40×106/mL (range, 0-345×106/mL) and the median
motility 50% (range, 0-90%). Sperm quality was good (concentration ≥20×106/mL and
motility ≥50%), intermediate (concentration ≥5×106/mL) and poor (concentration
<5×106/mL but >0) in 41%, 49% and 7% of patients, respectively. Three percent of the
patients were azoospermic. No relation was found between sperm quality and age or clin-
ical stage of the Hodgkin’s lymphoma, but B-symptoms and elevated erythrocyte sedi-
mentation rate predicted poor sperm quality. The odds ratios for the association of poor
sperm quality with the variables examined were: presence of B-symptoms, 2.77 (95% CI,
1.50-5.12; p=0.001); erythrocyte sedimentation rate of 50 mm/h or greater, 2.35 (95% CI,
1.24-4.43; p=0.009); fever, 3.22 (95% CI, 1.41-7.33; p=0.005), and night sweats, 3.78 (95%
CI, 1.97-7.26; p<0.001). There was no relation between sperm quality and pre-treatment
follicle stimulating hormone level.
Conclusions
In this large study of males with Hodgkin’s lymphoma, 90% had good or intermediate
sperm quality. Three percent were azoospermic. There was an association between sperm
quality and the presence or absence of B-symptoms, in particular fever and night sweats.
With modern fertilization techniques, in most patients with early-stage Hodgkin’s lym-
phoma sperm quality before treatment is good enough for future fatherhood.
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Introduction
Because Hodgkin’s lymphoma is often diagnosed in
patients in young adulthood whose cure rate is between
80 and 90%,1,2 preservation of fertility and semen cryo-
preservation are important.3 Not only chemotherapy,
but also the disease process itself appears to influence
spermatogenesis. Data from patients with Hodgkin’s
lymphoma hint that before treatment such patients have
lower sperm counts and reduced sperm motility com-
pared to healthy subjects,4,5 but data from large series of
patients are lacking; the largest series studied thus far
comprised 212 patients.6 The cause of the diminishment
in semen quality is not completely understood and has
been attributed to fever, poor performance, psychologi-
cal factors7,8 or even immune-mediated mechanisms.9
For many years gonadal toxicity has been studied in
trials by the European Organization for Research and
Treatment of Cancer (EORTC) Lymphoma Group and
the Groupe d’Étude des Lymphomes de l’Adulte (GELA).
This gave us the opportunity to study the spermatogen-
esis of a large cohort of male patients with early-stage
Hodgkin’s lymphoma prior to treatment. We compared
the quality of sperm in untreated patients with
Hodgkin’s lymphoma to that in various general popula-
tions. Secondly, we studied factors influencing sperm
quality and finally we analyzed the relation between
pre-treatment follicle stimulating hormone (FSH) con-
centration and sperm quality.
Design and Methods
Patients
All male patients with early stage classical Hodgkin’s
lymphoma included in the EORTC-GELA intergroup tri-
als H6, H7, H8 and H9 (1982-2004)10-13 were analyzed.
Patients were aged 15 to 70 years and presented with
histologically proven, previously untreated, clinical stage
I or II supradiaphragmatic Hodgkin’s lymphoma with
World Health Organization (WHO) performance status
grade 0-2. Patients with concomitant or previous malig-
nancies were excluded as were patients with serious co-
morbidity. Between August 1982 and May 2004, 2362
men were enrolled and registered in the EORTC-GELA
database. The studies were carried out in accordance
with the Helsinki Declaration. Protocols and informed
consent were approved by local ethical committees.
Data from sperm quality examinations conducted prior
to treatment were available for 474 men (20%). Of these
474 men, 35 participated in the H6, 77 in the H7, 181 in
the H8 and 181 in the H9 trial. For 205 out of the 474
men, FSH values before treatment were also available.
Collection and analysis of data
Data on demographic and Hodgkin’s lymphoma-relat-
ed variables were collected according to the EORTC-
GELA study protocols. For each patient, demographic
data, stage of the disease (I or II), presence of systemic
(B-) symptoms, erythrocyte sedimentation rate (ESR)
and smoking habits were recorded. Smoking was regis-
tered for patients in the H6, H8 and H9 trials and each
patient was defined as a current smoker (yes or no, H6
trial), or as never smoker, ever smoker who had stopped
smoking more than 10 years previously, ever smoker
who had stopped smoking less than 10 years ago, cur-
rent smoker for less than 10 years and current smoker
for more than 10 years (H8 and H9 trials). For the current
analysis, however, patients were re-coded as current or
not current smokers. B-symptoms were defined as the
presence of at least one of the following: weight loss of
more than 10% of ideal body weight within the preced-
ing 6 months, recurrent drenching night sweats during
the preceding months and unexplained, persistent or
recurrent fever exceeding 38°C for 8 days or more. For
the H6 trial, B-symptoms were not further specified; for
the H7, H8 and H9 trials a specification into the symp-
toms mentioned above was provided. Pre-treatment
FSH concentration was also measured in some, but not
in all, patients. Whether or not FSH was measured
depended on the recruiting hospitals’ participation in
toxicity analyses and was unrelated to patients’ charac-
teristics; hence, there was no selection bias involved.
FSH values were dichotomized (normal or elevated)
according to the normal values given by the laboratories
performing the analyses. Because normal values for FSH
are different in each laboratory, FSH levels were normal-
ized to render values comparable to one another by
dividing FSH by the individual upper normal value pro-
vided.
Sperm quality examinations
Sperm analyses were carried out at the laboratories of
the hospitals in which patients were treated. Patients
were included between August 1982 and May 2004.
During that period, no inter-laboratory quality control
systems were available. Sperm analysis was performed
before the semen was frozen. Sperm quality was
defined according to WHO guidelines14 and divided into
three categories: good quality if the sperm concentration
was 20×106/mL or greater and motility 50% or greater;
poor quality if the sperm concentration was less than
5×106/mL; and intermediate quality for all other concen-
trations except the complete absence of spermatozoa in
the ejaculate, which was classified as azoospermia.
Statistics
The aim of the study was to analyze factors influenc-
ing sperm quality in untreated patients with Hodgkin’s
lymphoma, and to analyze the relationship between
FSH and sperm quality and sperm concentration.
Ninety-five percent confidence intervals (95% CI) of the
proportions of patients within sperm quality categories
were calculated assuming a binomial distribution. An
analysis of factors influencing sperm quality was per-
formed using the Fisher’s exact test for categorical data
or Kruskal-Wallis test for age and ESR. Logistic regres-
sion models (univariate and multivariate analyses) were
constructed to assess the impact of independent co-vari-
ates on the sperm quality (good sperm quality and inter-
mediate sperm quality grouped together versus poor
sperm quality including azoospermia). Factors examined
were: patient’s age at measurement (both as a continu-
ous variable and divided into three groups ≤20 years ver-
sus 21-40 years versus >40 years), clinical stage (I versus
II), B-symptoms (absent versus present), fever (absent
versus present), weight loss (absent versus present), night
sweats (absent versus present), ESR (<50 mm/h versus
≥50 mm/h) and smoking status (non-current smokers
versus current smokers). 
A Kruskal-Wallis test was used to analyze the relation
between FSH and sperm quality. Spearman’s rank corre-
lation coefficient was used to assess the correlation
between FSH and sperm concentration. All statistical
tests were two-sided, and a p value less than 0.05 was
considered statistically significant. SAS statistical soft-
ware (release 9.1 TS Level 1M3; SAS Institute, Cary,
NC) was used to analyze data. Data were selected from
files stored at the Clinical Research Unit, Centre
François Baclesse, Caen, France and were updated on
January 1, 2006.
Results
Data from 474 male patients with early stage
Hodgkin’s lymphoma and a median age of 26 years
(range, 15-57 years) were available (Table 1). The
patients came from France (57%), the Netherlands
(31%), Belgium (7%), and the remaining 5% from
Slovenia, Switzerland, Portugal, Italy, Poland, the
United Kingdom and Croatia. Seventy percent had stage
II disease and 31% had B-symptoms. The median
sperm concentration was 40×106/mL (range, 0-
345×106/mL). The median motility was 50% (range, 0-
90%). WHO-defined sperm quality was good, interme-
diate and poor (concentration ≥20×106/mL and motility
≥50% for good, concentration >5×106/mL for intermedi-
ate, and concentration <5×106/mL but >0 for poor) in
41% (95% CI, 37-46%), 49% (95% CI, 45-54%) and
7% (95% CI, 4-9%) of patients, respectively, whereas
3% (95% CI, 2-5%) of the patients were azoospermic. 
For 77 (16%) of the patients, measurements of sperm
quality after treatment were also available. Interestingly,
in two patients who were azoospermic before treat-
ment we observed a complete recovery to normal
sperm quality after treatment (one patient at 18 months
after treatment, the other at 38 months after treatment).
The first patient was treated with six cycles of
MOPP/ABV hybrid (mechlorethamine, vincristine, pro-
carbazine, prednisone, doxorubicin, bleomycin, vinblas-
tine) chemotherapy and involved-field radiotherapy, the
second with six cycles of EBVP (epirubicin, bleomycin,
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Table 1. Patients’ characteristics in relation to sperm quality.
Sperm quality N (%) Good Intermediate Poor plus Poor Azoospermia Total p value * OR
azoospermia* (95% CI; p value)
195 (41%) 233 (49%) 46 (10%) 30 (7%) 16 (3%) 474
Median age, yrs (range) 27 (15-51) 26 (15-57) 26 (16-45) 27 (16-45) 25 (16-40) 26 (15-57) 0.518 ns§
Clinical stage 
I (%) 61 (31) 71 (30) 9 (20) 6 (20) 3 (20) 141 (30)
II (%) 133 (69) 162 (70) 36 (80) 24 (80) 12 (80) 331 (70) 0.316 ns
B-symptoms
No (%) 149 (76) 158 (68) 22 (48) 15 (50) 7 (44) 329 (69)
Yes (%) 46 (24) 75 (32) 24 (52) 15 (50) 9 (56) 145 (31) < 0.001 2.77
(1.50-5.12; 0.001)
Specification available 181 216 42 29 13 439
Fever 
No (%) 173 (96) 193 (89) 33 (79) 24 (83) 9 (69) 399 (91)
Yes (%) 8 (4)** 23 (11) 9 (21) 5 (17) 4 (31) 40 (9) 0.002 3.22
(1.41-7.33; 0.005)
Weight loss
No (%) 169 (93) 181 (84) 33 (79) 25 (86) 8 (62) 383 (87)
Yes (%) 12 (7) 35 (16) 9 (21) 4 (14) 5 (38) 56 (13) 0.002 ns
Night sweats 
No (%) 146 (81) 168 (78) 21 (50) 15 (52) 6 (46) 335 (76)
Yes (%) 35 (19) 48 (22) 21 (50) 14 (48) 7 (54) 104 (24) <0.001 3.78
(1.97-7.26; <0.001)
Median ESR, mm/h 17 25 30 37 26 21 0.005
ESR <50 mm/h (%) 155 (81) 174 (76) 28 (61) 19 (63) 9 (56) 357 (76)
ESR ≥50 mm/h (%) 36 (19) 56 (24) 18 (39) 11 (37) 7 (44) 110 (24) 0.016 2.30
(1.22-4.34; 0.010)
Current smoker 
No (%) 87 (68) 111 (66) 12 (50) 10 (56) 2 (33) 210 (65)
Yes (%) 41 (32) 58 (34) 12 (50) 8 (44) 4 (67) 111 (35) 0.240 ns
*For statistics, azoospermia was grouped within the category poor; §age was analyzed both as a continuous variable and divided into three groups: up to and including 20
years, 21 to 40 years and over 40 years of age; **patients could suffer from more than one B symptom; OR: univariate odds ratio for poor sperm quality; CI 95%: confidence
interval; ns: not statistically significant; ESR:erythrocyte sedimentation rate.
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vinblastine, prednisone) chemotherapy and involved-
field radiotherapy. 
No relation was found between sperm quality and
age, clinical stage (I or II) or smoking. However, the pres-
ence of B-symptoms and elevated ESR were linked with
poor sperm quality (p<0.001 and p=0.005). Each of the
three single B-symptoms (fever, weight loss and night
sweats) separately also had a statistically significant neg-
ative effect on sperm quality. By univariate logistic
regression, however, weight loss did not yield a statisti-
cally significant result whereas the association of fever
and night sweats with poor sperm quality remained sta-
tistically significant (Table 1). We performed multivari-
ate logistic regression analysis with B-symptoms and
ESR greater than 50 mm/h as independent factors,
resulting in B-symptoms as the only remaining explain-
ing variable (odds ratio (OR) 2.64, 95% CI 1.54-4.54;
p=0.003). Including fever, night sweats and ESR greater
than 50 mm/h in the model showed that night sweats
was the only remaining explaining variable (OR 3.78,
95% CI 2.19-6.54; p<0.001).
Of the 474 patients, 205 (43%) had pre-treatment data
on FSH available. The relation between FSH and sperm
concentration is plotted in Figure 1. Pre-treatment FSH
was elevated in only ten (5%) of the patients, of whom
four had a normal sperm concentration (≥20×106/mL),
four had a sperm concentration between 5×106/mL and
20×106/mL and two were azoospermic. The medians of
normalized FSH values were not statistically different
for the three sperm quality categories (p=0.328).
Spearman’s correlation for FSH and sperm concentration
was -0.139 (p=0.047).
Discussion
This study involved a very large group of male
patients whose sperm quality was analyzed before the
start of treatment for Hodgkin’s lymphoma. It appeared
that, with modern fertilization techniques, fatherhood
could be guaranteed for 97% of patients.
Sperm quality was not analyzed in all patients. This
was mainly dependent on the local hospitals and co-
ordinating physicians, and not on the patients’ charac-
teristics. To render data from a wide time span and
many different hospitals comparable, only data on
sperm concentration and progressive motility were ana-
lyzed. Sperm morphology assessment was considered
more subjective and thus less easily comparable
between laboratories than simple cell counts.
Ninety percent of patients with early stage Hodgkin’s
lymphoma had WHO-defined good or intermediate
sperm quality at disease presentation, whereas 7% of
patients had poor sperm quality and 3% of patients
were azoospermic. The median sperm concentration
was 40×106/mL and the median sperm motility was
50%. These values are seemingly normal, but probably
slightly below those in general population controls,
although data from such populations are limited. In fact,
most data on sperm quality in the general population
have been collected from selected groups of fertile men
volunteering as sperm donors or undergoing vasectomy
procedures.15,16 Moreover, sperm quality differs regional-
ly17 and is considered to be time-dependent, having
diminished over time during the last decades in devel-
oped countries.18,19 This last fact might be important as
sperm analysis took place between 1982 and 2004.
Finally, since sperm concentration and motility are not
normally distributed, median values were used in the
present study20 instead of mean values frequently used
by others, hampering easy numerical comparisons.21-24
There are only few data concerning a non-selected
population, i.e. a population without proven fertility,
against which to compare those of the patients in our
study. The only two completely random samples came
from Denmark, but the sperm quality of men in this
country is reputed to be among the lowest in Europe.25 It
appeared that the median concentration and motility of
sperm from our study population were in line with
those of sperm from non-selected, young Danish men,
either undergoing an examination for military service26
or being Danish trade union members without children
or known fertility problems.27
Nowadays, patients with intermediate or poor quality
sperm are still eligible to enter sperm cryopreservation
programs with a view to subsequent in vitro fertilization
or intracytoplasmatic sperm injection. The only serious
problem for future fertility encountered in our study
cohort was constituted by the 3% of cases with
azoospermia, since this obviously excludes cryopreser-
vation.28 The incidence of azoospermia in the general
population is not known, but is often assumed to be 2%,
mainly based on a study conducted on forensic evidence
from 519 rape cases.29
Compared to previous studies in patients with
Hodgkin’s lymphoma, our data showed better sperm
quality than in some analyses,6,30 but worse quality than
in others.7,31,32 Our study was, however, based on data
from by far the largest series studied up date; this offered
not only a more reliable estimation of sperm quality but
Figure 1. Sperm quality and FSH level before treatment. Sperm
quality was divided into three categories: good quality if concen-
tration of spermatozoa was ≥20×106/mL and motility ≥50%; poor
quality if concentration of spermatozoa was <5×106/mL; interme-
diate quality for all other concentrations, except azoospermia.
First vertical reference line: sperm concentration: 5×106/mL.
Second vertical reference line: sperm concentration: 20×106/mL.
Horizontal reference line: FSH: upper normal value; values above
this line indicate elevated FSH and values below this line indicate
non-elevated FSH. Two outliers are present; norm. FSH: normal-
ized FSH. 
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also the opportunity to study factors influencing sperm
quality. Neither of the two groups5,32 that tried to ana-
lyze the influence of B-symptoms and fever on sperm
quality before treatment found a significant difference
between patients with or without these manifestations,
most probably due to limited sample sizes (92 and 94
patients, respectively). Our data show that poor sperm
quality is strongly associated with the presence of B-
symptoms, in particular fever and night sweats, which
might in part be related to the well-known adverse
effect of elevated scrotal temperature on spermatogene-
sis.33 Given that patients with fever nearly always had
night sweats as well, it was not possible to determine
which of the individual B-symptoms had the strongest
impact. Another limitation of our study is that only
patients with early stage disease were enrolled: two
other studies30,34 previously showed that advanced-stage
disease has a greater negative effect than early-stage dis-
ease on semen quality. 
Previously we observed that elevated FSH levels cor-
relate well with poor spermatogenesis after treatment,35
but in our present study this relationship apparently did
not exist before treatment. This is confirmed by the
scarce observations in the literature5,6,30 and means that
whereas semen quality after cancer therapy is poor due
to damage to the gonadal structures, there must be
another reason to explain diminished sperm quality
before treatment. Poor sperm quality in cancer patients
is assumed to be related to hypothalamic dysfunction
caused by the systemic illness, catabolic state and mal-
nutrition.8,36 In addition, there is a postulated effect of
both circulating cytokines30 and an imbalance of sub-
populations of T lymphocytes, which may be involved
in spermatogenesis.9 Here, we have shown that fever, if
present, contributes as well in patients with Hodgkin’s
lymphoma. The fact that sperm quality is threatened by
two completely different mechanisms before and after
treatment means that even in patients with very poor
quality sperm before treatment, fertility after treatment
could be excellent if cancer therapy (for instance ABVD
(doxorubicin, bleomycin, vinblastine, dacarbazine)
chemotherapy) is not gonadotoxic.35 Our finding of two
patients who were azoospermic before treatment but
had normal sperm quality after treatment is in agree-
ment with this theory. Thus, it is still worthwhile select-
ing non-gonadotoxic therapy for men with Hodgkin’s
lymphoma, even if they are infertile before treatment.
A large Life Situation Questionnaire has been
designed by the EORTC-GELA Lymphoma Group to
further analyze fertility and fatherhood after therapy
among patients with Hodgkin’s lymphoma. 
In conclusion, in most patients with early stage
Hodgkin’s lymphoma, sperm quality before treatment
is not a problematic issue and cryopreservation should
be encouraged.
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Appendix
Patients were included by the following centers:
France (n=270), Institut Gustave Roussy, Villejuif,
(n=37) (P. Carde, C. Fermé); Hôpital Saint-Louis, Paris
(n=21), (P. Brice); CHU Nancy Hôpital Brabois, Vandoeuvre-
les-Nancy (n=18) (P. Léderlin); Centre François Baclesse,
Caen (n=16) (A. Tanguy); Institut Bergonié, Bordeaux (n=13)
(H. Eghbali); CHU de Besançon Hôpital Jean Minjoz,
Besançon (n=12) (L. Voillat); CHU Clémenceau, Caen
(n=11) (O. Reman); Centre Hospitalier René Dubos, Pontoise
(n=11) (Y.J.P. Kerneis); Centre Hospitalier de Chambéry,
Chambéry (n=10) (M. Blanc); Hôpital Henri Mondor, Créteil
(n=7) (M. Diviné); Hôpital Saint-Antoine, Paris (n=7) (M.
Aoudjhane); Centre Hospitalier Lyon Sud, Pierre-Bénite (n=7)
(G. Salles); Centre Alexis Vautrin, Vandoeuvre-les-Nancy
(n=7) (T. Conroy); CHRU de Lille Hôpital Claude Huriez,
Lille (n=6) (F. Morschauser); Hôpital Edouard Herriot, Lyon
(n=6) (J. Troncy); Centre Léon Bérard, Lyon (n=5) (C.
Sebban); CHU Saint-Etienne Hôpital Nord, Saint-Etienne
(n=5) (J. Jaubert); Hôpital Bicêtre, Le Kremlin-Bicêtre (n=4)
(G. Tertian); Institut J. Paoli & I. Calmettes, Marseille (n=4)
(R. Bouabdallah); Centre Hospitalier Régional de Metz-
Thionville, Metz (n=4) (B. Christian); Centre Antoine
Lacassagne, Nice (n=4) (A. Thyss); Centre René Huguenin,
Saint-Cloud (n=4) (M. Janvier); Centre Médico-Chirurgical
Foch, Suresnes (n=4) (E. Baumelou); Centre Hospitalier
d’Annecy, Annecy (n=3) (C. Martin); Hôpital Gilles de
Corbeil, Corbeil-Essonnes (n=3) (A. Devidas); CHU Dijon,
Dijon (n=3) (R.O. Casanovas); Centre Georges-François
Leclerc, Dijon (n=3) (P. Fargeot); CHU de Limoges Hôpital
Dupuytren, Limoges (n=3) (D. Bordessoule); Hôpital Pitié-
Salpétrière, Paris (n=3) (J. Gabarre); Centre Hospitalier de
Compiègne, Compiègne (n=2) (D. Zylberait); Centre
Hospitalier de Dunkerque, Dunkerque (n=2) (M.
Wetterwald); Clinique du Mail, Grenoble (n=2) (D.
Assouline); CHU de Montpellier Saint-Eloi, Montpellier
(n=2) (P. Quittet); Centre Val d’Aurelle Paul Lamarque,
Montpellier (n=2) (M. Fabbro); Institut Curie, Paris (n=2) (J.
Dumont); Hôpital Necker, Paris (n=2) (R. Delarue); Centre
Henri Becquerel, Rouen (n=2) (A. Stamatoullas); Centre
Hospitalier de Valence, Valence (n=2) (P-Y. Péaud); Centre
d’Oncologie et de Radiothérapie de Chaumont-le-Bois,
Chaumont (n=1) (G. Dupont); Hôpital Pasteur, Colmar (n=1)
(B. Audhuy); Hotel-Dieu du Creusot, Le Creusot (n=1) (Dr.
Gabez); Centre Hospitalier Robert Boulin, Libourne (n=1) (K.
Bouabdallah); CHU Hôpital l’Archet, Nice (n=1) (P.
Heudier); Hôpital Cochin, Paris (n=1) (F. Dreyffus); Hotel-
Dieu, Paris (n=1) (A. Delmer); Hôpital Lariboisière, Paris
(n=1) (J-M. Zini); CHU de Bordeaux Hôpital Haut-Lévèque,
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Pessac (n=1) (G. Marit); Hôpital de Saint-Germain-en-Laye,
Saint-Germain-en-Laye (n=1) (M. Azagury); CHU de
Toulouse Hôpital Purpan, Toulouse (n=1) (M. Attal). The
Netherlands (n=147) Leids Universitair Medisch Centrum,
Leiden (n=32) (J.C. Kluin-Nelemans, R. Willemze); NKI,
Antoni van Leeuwenhoek Ziekenhuis, Amsterdam (n=16)
(J.W. Baars) Erasmus Medisch Centrum, Rotterdam (n=15)
(P.J. Lugtenburg, M.B. van ’t Veer); Medisch Spectrum
Twente, Enschede (n=9) (J.H. Meerwaldt); Universitair
Medisch Centrum Utrecht, Utrecht (n=9) (A. Hagenbeek);
Isala Klinieken, Zwolle (n=7) (R. van Marwijk Kooy); St
Antonius Ziekenhuis, Nieuwegein (n=6) (D.H. Biesma);
Academisch Medisch Centrum, Amsterdam (n=5) (M.H.J. van
Oers); Onze Lieve Vrouwe Gasthuis, Amsterdam (n=5) (K.J.
Roozendaal); Medisch Centrum Leeuwarden, Leeuwarden
(n=5) (P. Joosten); Meander Medisch Centrum location
Lichtenberg, Amersfoort (n=4) (M.H.H. Kramer); Universitair
Medisch Centrum Groningen, Groningen (n=4) (G.W. van
Imhoff); Reinier de Graaf Gasthuis, Delft (n=3) (E.F.M.
Posthuma); HagaZiekenhuis location Leyweg, Den Haag
(n=3) (P.W. Wijermans); Amphia Ziekenhuis location
Molengracht, Breda (n=2) (A.C.J.M. Holdrinet); Jeroen Bosch
Ziekenhuis, Den Bosch (n=2) (H.A.M. Sinnige);
HagaZiekenhuis location Rode Kruis, Den Haag (n=2) (W.A.
van Deijk); Catharina Ziekenhuis, Eindhoven (n=2) (G-J.
Creemers); Groene Hartziekenhuis, Gouda (n=2) (R.F.A.
Simonis); Spaarne Ziekenhuis, Hoofddorp (n=2) (C.A.M. de
Swart); Diaconessenhuis, Leiden (n=2) (H. van Slooten); St
Anna Ziekenhuis, Geldrop (n=1) (R.E.H. Smeets); Martini
Ziekenhuis, Groningen (n=1) (H. Piersma); Atrium Medisch
Centrum location Heerlen, Heerlen (n=1) (M. Fickers);
Tergooiziekenhuizen locatie Hilversum; Hilversum (n=1)
(H.M. Muller); Medisch Centrum Haaglanden location
Antoniushove, Leidschendam (n=1) (M.G. Herben);
Universitair Medisch Centrum St Radboud, Nijmegen (n=1)
(J. Raemaekers); Maasland Ziekenhuis, Sittard (n=1)
(H.N.L.M. Bron); Ziekenhuis Bernhoven, location Veghel,
Veghel (n=1) (L.H. Hulsteijn); Máxima Medisch Centrum
location Veldhoven (n=1) (J.J. Keuning); Diaconessenhuis,
Voorburg (n=1), (E.F.M. Posthuma). Belgium (n=35) UZ
Gasthuisberg, Leuven (n=13) (J. Thomas); Universitair
Ziekenhuis Antwerpen, Edegem (n=6) (W. Schroyens); Institut
Jules Bordet, Bruxelles (n=4) (D. Bron); Centre Hospitalier
Notre Dame et Reine Fabiola, Charleroi (n=3) (M. André);
Cliniques Universitaires Saint-Luc, Bruxelles (n=2) (A.
Ferrant); Cliniques Universitaires de Mont-Godinne, Yvoir
(n=2) (A. Bosly); ZNA Middelheim, Antwerpen (n=1) (R. de
Bock, P. Meijnders); AZ St Jan, Brugge (n=1) (A. van Hoof);
Hôpital Saint-Joseph, Gilly (n=1) (P. Mineur); Centre
Hospitalier Régional Clinique Saint-Joseph, Mons (n=1) (D.
Boulet); Clinique Sainte-Elisabeth, Namur (n=1) (V.
Mathieux). Other countries (n=22) Slovenia, Institut of
Oncology, Ljubljana (n=9) (R. Tomsac, M. Vovk);
Switzerland, CHU Vaudois, Lausanne (n=4) (N. Ketterer);
Portugal, Instituto Portugues de Oncologia, Porto (n=3) (F.
Viseu); Poland, Curie Memorial Cancer Centre, Warsaw
(n=2) (J. Meder, J. Walewski); Croatia, University, Hospital
Rebro, Zagreb (n=1) (I. Aurer); Italy, Centro di Riferimento
Oncologico, Aviano (n=1) (U. Tirelli); Italy, Ospedale S.
Maria Delle Croci, Ravenna (n=1) (G. Rosti); United
Kingdom, General Hospital, Southampton (n=1) (M.
Whitehouse).
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